The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non‐small cell lung cancer treated with immune checkpoint inhibitors

• Published in: Thoracic cancer Vol. 14; no. 1; pp. 52 - 60
• Main Authors: Yang, Jieun, Kim, Se Hyun, Jung, Eun Hee, Kim, Sang‐A, Suh, Koung Jin, Lee, Ji Yun, Kim, Ji‐Won, Kim, Jin Won, Lee, Jeong‐Ok, Kim, Yu Jung, Lee, Keun‐Wook, Kim, Jee Hyun, Bang, Soo‐Mee, Lee, Jong Seok
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.01.2023; John Wiley & Sons, Inc; Wiley
• Subjects: Antidiabetics; Antineoplastic Agents, Immunological - therapeutic use; Cancer therapies; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Clinical outcomes; Diabetes; dipeptidyl peptidase 4 inhibitor; Dipeptidyl-Peptidase IV Inhibitors - pharmacology; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Humans; immune checkpoint inhibitor; Immune Checkpoint Inhibitors - therapeutic use; Kinases; Ligands; Lung cancer; Lung Neoplasms - pathology; Metastasis; metformin; Metformin - pharmacology; Metformin - therapeutic use; non‐small cell lung cancer; Original; Patients; Proteins; Survival analysis; Tumors; non-small cell lung cancer; dipeptidyl peptidase 4 inhibitor; metformin; immune checkpoint inhibitor

Background Preclinical data have shown the immunomodulatory effects of metformin and dipeptidyl peptidase 4 (DPP4) inhibitors in patients with diabetes. However, its clinical impact remains unclear in lung cancer. Methods Between 2017 and 2021, 466 patients received ICI monotherapy. Patients were ca...